in a previous study of patients with recurrent or disseminated non-small-cell lung cancer ( nsclc ) , the combination of bleomycin , etoposide , and cisplatin ( bep ) produced objective responses in ten of 17 ( 59 % ) patients with large-cell anaplastic carcinoma and in 14 of 35 ( 40 % ) with squamous-cell carcinoma .
C0008838
cisplatin
C0053334
bep